Show summary Hide summary
A medication originally designed to treat a scarring lung disease produced unexpected changes in patients’ blood that, by several biological “aging clocks,” made them look years younger. The result — reported this week in Nature Biotechnology and discussed at a Nature meeting in Paris — raises questions about whether a lung drug could influence aging, but scientists stress the evidence is preliminary.
The drug, known as rentosertib, was developed using artificial intelligence and is being tested for idiopathic pulmonary fibrosis (IPF), a progressive lung condition. In a small, early-stage clinical trial, people receiving the drug showed shifts in blood protein patterns that several independent tests interpreted as a younger biological age.
Northern Illinois 9/11 25th anniversary: schedule of local ceremonies
Aaron Judge back: Yankees surge into World Series contention
What the trial found
Researchers analyzed 42 patients over roughly 12 weeks and applied six different aging assays to blood samples. On average, treated participants ranked about three to four years “younger” by those measures; one participant’s result suggested as much as a six-year change. The clearest signal emerged after four weeks in patients taking 30 mg twice daily.
| Feature | Details |
|---|---|
| Study type | Pilot randomized trial; 42 patients with IPF; 12-week follow-up |
| Primary observation | Shifts in blood proteins consistent with reduced biological age on multiple clocks |
| Strongest effect | 30 mg, twice daily; most pronounced at four weeks |
| Comparative data | Protein changes contrasted with >55,000 records from UK Biobank |
| Current status | Drug in a year-long phase 3 trial in China (>300 patients) |
Why scientists are cautious
Investigators describe the results as exploratory. The trial was small and restricted to people with IPF — a disease that itself alters many circulating proteins used to estimate biological age — so it’s difficult to separate a true anti-aging signal from improvements in lung health.
All observed changes were measured in blood protein profiles; there is no evidence yet that rentosertib extends lifespan or improves long-term health outcomes. The authors and outside experts emphasize that larger, longer studies including healthy older adults are needed before drawing conclusions about anti-aging effects.
- Sample size limitation: Only 42 patients — results may not generalize.
- Confounding by disease: IPF itself could drive biomarker shifts independent of aging mechanisms.
- Biomarker vs. outcome: Protein changes are surrogate signals, not proof of longer, healthier life.
Mechanism and company approach
Insilico Medicine, the company behind rentosertib, used machine learning to identify molecular targets they say may link disease biology and aging processes. The team describes targeting what its researchers call detrimental biological pathways that contribute to both tissue damage and age-related decline.
The study involved collaborators from institutions including Harvard Medical School, Stanford, the Broad Institute and several international universities. The research was published in Nature Biotechnology and presented at a conference held at Sorbonne University.
Safety and next steps
Company clinicians reported that side effects observed so far were manageable. The most commonly noted issues were mild diarrhea, modest reductions in blood potassium and temporary rises in liver enzymes. Investigators said dose adjustments will be explored to improve tolerability for longer treatment periods.
Insilico has advanced the drug into a larger phase 3 study lasting one year and enrolling more than 300 patients in China. But to test the broader anti-aging hypothesis, researchers say future trials must include people without IPF and follow participants for longer to assess clinical benefits beyond biomarker shifts.
For now, the headline is cautious: an AI-designed lung drug produced intriguing biomarker changes that resemble younger biological age, but confirmation will require rigorous, well-powered trials before any claim that rentosertib slows human aging can be supported.
